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Abstract
Background: Hospital-acquired acute kidney injury (AKI) in humans and dogs
increases morbidity and nonsurvival. Azotemia at presentation has been associated
with a poor outcome in horses; however, prevalence and consequences of hospital-
acquired AKI are unreported.
Hypothesis/Objectives: To evaluate the prevalence of AKI in hospitalized horses, risk
factors associated with AKI, and the effect of AKI on short-term survival. We hypoth-
esized that the prevalence of AKI in horses is similar to that reported in other domes-
tic mammalian species and would be associated with nonsurvival.
Animals: Adult horses hospitalized for >2 days from which a minimum of 2 measure-
ments of serum creatinine concentration were available.
Methods: Retrospective cohort study. Clinical records were reviewed and horses
grouped according to their baseline serum creatinine concentration and change in
serum creatinine concentration from baseline. The associations between signalment,
diagnosis, and treatment variables, and the presence of azotemia or AKI were
assessed using multinomial logistic regression. The relationship between these condi-
tions and survival to discharge was evaluated.
Results: Three hundred twenty-five horses were included; 4.3% (14/325) had azotemia
at baseline and 14.8% (48/325) developed AKI. There were no significant associations
between investigated risk factors and development of AKI. The presence of azotemia
and AKI did not significantly affect survival to discharge (P = .08 and .81, respectively).
Conclusions and Clinical Importance: The prevalence of AKI in this population of
hospitalized horses is similar to that reported in dogs and humans; however, in this
study population, there was less impact on morbidity and short-term survival.
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1 | INTRODUCTION
Acute kidney injury (AKI) is a common and clinically important compli-
cation in hospitalized human patients. In humans, the prevalence of
Abbreviations: AKI, acute kidney injury; CI, confidence interval; GFR, glomerular filtration
rate; KDIGO, kidney disease improving global outcomes; NSAID, nonsteroidal anti-
inflammatory; OR, odds ratio; sCr, serum creatinine concentration; SDMA, symmetric
dimethylarginine; SIRS, systemic inflammatory response syndrome; VAKI, veterinary acute
kidney injury.
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AKI varies depending on the definition used and the population stud-
ied, but can be as high as 67% in intensive care settings.1 Acute
kidney injury increases morbidity and nonsurvival, duration of hospi-
talization, and cost of treatment.2,3 An increase in serum creatinine
concentration (sCr) of 0.3 mg/dL (26.5 μmol/L) increases the risk of
death by 70% in hospitalized humans.2 Patients with sepsis or cardiac
disease are particularly susceptible.4,5 These results are mirrored in
dogs, where the prevalence of AKI was 14.9% and the diagnosis cor-
responded with an increase in nonsurvival from 15.7% to 54.2%.6 In
horses, severe (>10 mg/dL) or persistent (duration over 72 hours) azo-
temia has been associated with a poor outcome; however, smaller
changes in sCr that could identify development of hospital-acquired
AKI have not been assessed.7,8
Historically, variations in the definition of AKI have made consis-
tent identification and classification of patients difficult. Recently,
however, the Kidney Disease Improving Global Outcomes (KDIGO)
group defined AKI in humans as any of the following: (1) increase in
sCr by 0.3 mg/dL (26.5 μmol/L) or more within 48 hours, (2) increase
in sCr 1.5 times baseline or more within 7 days, or (3) oliguria
(<0.5 mL/kg/h) for 6 hours.9 Importantly, this definition recognizes
that kidney injury is a dynamic process and that sCr can remain within
the reference range despite AKI. These criteria have been adapted for
use in veterinary medicine to create the Veterinary Acute Kidney
Injury (VAKI) scoring system, which has been used in dogs.6
Kidney injury in horses has been identified as a complication of
hypovolemia, administration of nephrotoxic drugs, diarrhea or colitis,
and sepsis.8,10-13 The objectives of the current study were (1) to apply
the VAKI scoring system to a population of hospitalized horses to
identify the prevalence of AKI, (2) to identify risk factors associated
with the development of AKI, and (3) to assess the association of AKI
with short-term survival.
We hypothesized that the prevalence of AKI in hospitalized horses
would be 15%-25% (extrapolated from studies performed in adult
humans and dogs), and that the presence of AKI would be associated
with a decreased short-term survival.6,14 We hypothesized that the
administration of drugs with known nephrotoxic effects would be
associated with increased AKI.
2 | MATERIALS AND METHODS
This was a single-center, retrospective cohort study. Medical records
of all horses admitted to Rossdales Equine Hospital between August
2015 and January 2019 were reviewed. Power calculation using vari-
ance and effect size data from canine and human AKI characterization
studies identified that a sample size of 119 horses would be required
to reliably detect a 15% prevalence of AKI with 80% power and 95%
confidence. Horses were included for further analysis if they had an
sCr measurement within 24 hours of admission (baseline sCr) and at
least 1 more sCr measurement in the first 7 days of hospitalization.
Cases were excluded if they were admitted with a history suggestive
of primary renal disease, were less than 3 months of age, or were hos-
pitalized for less than 2 days.
Variables identified from case records included signalment (sex,
breed, age, and weight). Clinical variables (heart rate, respiratory rate,
and temperature) and laboratory data (PCV, total solids, peripheral lac-
tate concentration, and leukocyte count) on admission were used
to assess systemic inflammatory response and the presence of
hypovolemia. Hypovolemia was defined as horses showing 2 of the
following 3 variables: tachycardia (>60 beats/min), PCV >45%, and
peripheral lactate >31.5 mg/dL (3.5 mmol/L).15 Systemic inflammatory
response syndrome (SIRS) was defined as the presence of 2 or more
abnormalities, including hyperthermia (>38.5C) or hypothermia
(<37.0C), tachycardia (>45 beats/min), tachypnea (>20 breaths/min),
leukopenia (leukocyte count <6000/μL), and leukocytosis (leukocyte
count >12 000/μL).16
Emergency admissions were differentiated from those admitted
for elective procedures. Diagnoses were recorded and categorized as
small intestinal lesion, large intestinal lesion (excluding colon torsion),
colon torsion, peritonitis, other abdomen, respiratory, orthopedic,
reproductive, and “other.” Horses with >1 condition were included in
all appropriate diagnostic categories and the total number of diagno-
ses was recorded.
Treatment variables included the number of general anesthesia
episodes, administration of potentially nephrotoxic drugs (nonsteroi-
dal anti-inflammatory drugs [NSAIDs], gentamicin, tetracyclines,
polymyxin B, and synthetic colloids), and whether crystalloid IV fluid
therapy was administered. Duration of hospitalization and survival to
discharge were recorded.
Creatinine concentrations were measured in serum samples in a
single laboratory using the Jaffe reaction with alkaline picrate (IL ILab
IL650 Chemistry Analyzer; Instrumentation Laboratory, Lexington,
Massachusetts). Azotemia was defined as any horse with a baseline
sCr >1.9 mg/dL (167 μmol/L).17 Azotemia was considered secondary
to a primary disease when there was no history suggesting preexisting
renal injury, and other clinical abnormalities were likely to have led
to AKI.
Horses were categorized into groups for statistical analysis according
to their kidney status as follows:
• Azotemia on baseline; sCr measurement >1.9 mg/dL (167 μmol/L).
These were analyzed separately to those that developed AKI in
hospital.
• For horses that did not have azotemia on baseline sCr measure-
ment, AKI staging was performed using the VAKI staging system.6
 Stage 0 (S0): increase in sCr <150% from baseline
 Stage 1 (S1): increase in sCr of 150%-199% or an absolute
increase in sCr 0.3 mg/dL (≥26.5 μmol/L) from baseline
 Stage 2 (S2): increase in sCr from 200-299% from baseline
 Stage 3 (S3): increase in sCr of ≥300% from baseline or an abso-
lute sCr 4.0 mg/dL (>354 μmol/L).
For horses with >2 sCr measurements during the hospitalization
period, the sCr value with the greatest deviation from baseline was
used to calculate the change in sCr. If sCr only decreased during
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hospitalization, the maximum change in sCr was recorded as a nega-
tive value.
2.1 | Statistical analysis
Analysis was performed using the statistical software package R
(Version 3.4.4; R Inc., Boston, Massachusetts). The single outcome
variable was kidney status (S0, S1, S2, S3, or azotemia). Due to the
small number of horses in groups S2 and S3, for the purposes of sta-
tistical analysis, S1, S2, and S3 horses were grouped together (S1-S3).
Independent variables assessed included signalment, diagnostic and
treatment categories as described above. For continuous variables
(age, duration of hospitalization), the median and interquartile range
were reported and a Kruskal-Wallis test was applied for statistical
analysis of associations with kidney status. All other variables con-
tained categorical data, which was analyzed using either a chi-square
test or Fisher's exact test depending on the number of animals in each
subgroup. A Bonferroni correction for multiple testing was applied to
the results. Multinomial logistic regression was used to assess associa-
tions between kidney status and all of the signalment, diagnostic and
treatment categories independently: variables where associations with
the dependent variable had a P-value of .2 or less were used in the ini-
tial multivariable model. Variables were subsequently removed in a
stepwise fashion where P-value for an effect was less than .2. In order
to avoid overfitting, the final model included main effects only with-
out interactions. The effect of kidney status on survival to discharge
was analyzed using a Kaplan-Meier survival curve and a log-rank test.
P-value <.05 was considered statistically significant.
3 | RESULTS
3.1 | Study population
A total of 325 horses were included. Age was known for 316 horses
(median 9 years; range 3 months-24 years); 66 horses were ≥15 years,
195 were 3-14 years, and 55 were 3 months to 2 years of age. There
were 160 females, 156 males (125 geldings and 31 stallions), and
9 unrecorded. Breeds included Thoroughbreds (141), Warmbloods
(30), Ponies (28), Cob (31), Sports-horse (45), other (37), and 13
unrecorded. Three horses were excluded due to primary renal disease,
which had been identified before admission and was the reason for
referral.
Horses were admitted as an emergency on 300 occasions (92.3%);
25 horses were admitted for elective procedures. Intra-abdominal dis-
ease was diagnosed in 272 instances: 86 small intestinal, 111 large
intestinal, 27 colon torsion, 23 peritonitis, and 25 other abdominal;
34 had a respiratory diagnosis; 42 orthopedic; 25 reproductive; and
55 had “other” diagnoses. Multiple diagnoses were present in 102
horses, 82 of which had 2 diagnoses, 17 had 3 diagnoses, and 3 had
4 diagnoses.
One hundred seventy-nine horses underwent general anesthesia,
of which 19 horses were anesthetized twice or more. Drugs with
reported potential for nephrotoxicity were administered to 294 horses;
NSAIDs (n = 294), gentamicin (n = 219), tetracycline antibiotic (n = 43),
polymyxin B (n = 28), and synthetic colloids (n = 38). Intravenous iso-
tonic fluid therapy was administered to 234 horses. The median dura-
tion of hospitalization was 8 days (range 2-48 days; Table 1).
Of the 325 horses, hypovolemia was identified in 43 on admission,
171 did not have evidence of hypovolemia, and for 112 horses, data
were insufficient. Of the 43 hypovolemic horses, 4 had azotemia on
admission and 5 developed AKI during hospitalization.
Evidence of SIRS was found in 80 of 325 horses. Of the
325 horses, 124 did not have evidence of SIRS and for 121 data were
insufficient to assess. Of the 80 horses with SIRS, 5 had azotemia and
8 developed AKI. For horses where SIRS status was known, P for a
statistical association between the presence of SIRS and development
of AKI was .05 (odds ratio [OR], 0.41; 95% confidence intervals [CI],
0.15-1.01) and .32 for an association between the presence of SIRS
and azotemia (OR, 1.99; 95% CI, 0.41-10.4). For horses with SIRS,
azotemia and the development of AKI were not associated with sur-
vival to discharge (P = .99 and P = .68, respectively).
3.2 | Kidney status
Of the 325 horses, 4.3% (14 horses; 95% CI 2.1-6.5) had azotemia on
baseline sCr (mean 2.4 mg/dL, range 1.9-3.5 mg/dL). Serum creatinine
normalized during hospitalization for all horses with azotemia. As
defined by the VAKI staging system, 80.9% (263/325; 95% CI,
76.7-85.2) were S0, 13.5% (44/325; 95% CI, 9.8-17.3) were S1, and
1.2% (4/325; 95% CI, 0.03-2.4) were S2. No horses in this study were
S3. The overall prevalence of AKI in this population was 14.8% (95%
CI, 10.9-18.6).
3.3 | Risk factors
In an exploratory analysis using chi-square tests, azotemia was signifi-
cantly associated with the number of diagnoses and treatment with
synthetic colloids (P = .01 and P = .02, respectively). S1-S3 was signifi-
cantly associated with treatment with tetracycline antibiotics (P = .01;
Table 1). However, applying a Bonferroni correction for multiple test-
ing removed significance for these variables.
Following univariable analysis, multinomial logistic regression was
used to assess factors associated with the risk of AKI (3 levels of kid-
ney status: S0, S1-S3, or azotemia). Factors included in the multino-
mial model (P < .2) included breed, SIRS, hypovolemia, small intestine
and other abdominal diagnoses, number of diagnoses, treatment with
gentamicin or tetracycline antibiotics, and the number of general
anesthetics. After stepwise removal of variables where P > .2, the final
multivariable model included SIRS (P = .06), hypovolemia (P = .08),
number of diagnoses (P = .17), and treatment with tetracycline antibi-
otics (P = .16; Table 2).
3.4 | Survival
Overall survival to discharge was 87.7% (285/325; 95% CI,
83.7-90.1). For S0 horses, survival was 88.6% (233/263; 95% CI,
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TABLE 1 Characteristics, diagnoses, and treatments of 325 hospitalized horses according to their kidney status
Variable
Stage 0
Stages 1-3 Azotemia at baseline
n (%) n (%) P n (%) P
Signalment
Sex n = 254 n = 48 .68 n = 13 .99
Mare 102 (40.2) 17 (35.4) 6 (46.2)
Gelding 128 (50.4) 25 (52.1) 6 (46.2)
Stallion 24 (9.4) 6 (12.5) 1 (7.7)
Breed n = 252 n = 47 .12 n = 13 .24
Thoroughbred 118 (46.8) 19 (40.4) 4 (30.8)
Warmblood 20 (7.9) 8 (17.0) 2 (15.4)
Pony 24 (9.5) 4 (8.5) 0
Cob 29 (11.5) 1 (2.1) 1 (7.7)
Sports Horse 34 (13.5) 9 (19.1) 2 (15.4)
Other 27 (10.7) 6 (12.7) 4 (30.1)
Age (years)a 9 (0-24) 9 (0-20) .99 13 (0-19) .97
Laboratory parameters
SIRS n = 160 n = 35 .05 n = 9 .32
67 (41.8) 8 (22.9) 5 (55.6)
Hypovolemia n = 166 n = 38 .36 n = 10 .12
34 (20.5) 5 (13.2) 4 (40)
Diagnosis n = 263 n = 48 n = 14
Small intestinal 64 (24.3) 17 (35.4) .11 5 (35.7) .53
Large intestinal 88 (33.4) 16 (33.3) .99 7 (50) .25
Colon torsion 23 (8.7) 4 (8.3) .99 0 .62
Peritonitis 19 (7.2) 4 (8.3) .77 0 .61
Other abdominal 20 (7.6) 2 (4.2) .55 3 (21.4) .08
Respiratory 30 (11.4) 4 (8.3) .80 0 .38
Orthopedic 36 (13.7) 4 (8.3) .36 2 (14.2) .70
Reproductive 19 (7.2) 4 (8.3) .77 2 (14.2) .29
Number of diagnoses .47 .01*a
1 183 (69.5) 35 (72.9) 5 (35.7)
2 66 (25.1) 9 (18.8) 6 (42.3)
≥3 14 (5.3) 4 (8.3) 3 (21.4)
Treatment n = 263 n = 48 n = 14
Number of general anesthetic episodes .21 .12
0 120 (45.6) 18 (37.5) 8 (57.1)
1 131 (49.8) 25 (52.1) 4 (28.6)
≥2 12 (4.6) 5 (10.4) 2 (14.3)
NSAIDs 236 (89.7) 45 (93.8) .59 13 (92.9) .99
Gentamicin 174 (66.2) 37 (77.1) .18 8 (57.1) .40
Tetracycline 41 (15.6) 1 (2.1) .01* 2 (14.3) .70
Polymyxin B 23 (8.7) 4 (8.3) .99 1 (7.1) .99
Synthetic colloids 30 (11.4) 3 (6.3) .44 5 (35.7) .02*
Duration of hospitalization (days)a 8 (2-48) 11 (2-29) .62 7 (3-21) .44
P-values identify univariable associations between S0 and S1-S3 or azotemia, respectively.
Abbreviations: n, number in subset; NSAIDs, nonsteroidal anti-inflammatory drugs; SIRS, Systemic inflammatory response syndrome.
*P-values <.05 indicate a statistically significant difference when compared to S0 group.;
a
Kruskal-Wallis applied for continuous variables; median and
range reported.
SAVAGE ET AL. 2297
84.2-91.9). For S1-S3 horses, survival was 87.5% (42/48; 95% CI,
75.3-94.1). For azotemia horses, survival was 71.4% (10/14; 95% CI,
45.4-88.3). Survival to discharge was not significantly different
between S0 and horses with azotemia (P = .08) and between S0 and
S1-S3 horses (P = .81; Figure 1).
4 | DISCUSSION
4.1 | Prevalence
Using the VAKI criteria, the prevalence of AKI in this population of
hospitalized horses was 14.7% (95% CI, 10.9-18.6). This is lower than
the reported prevalence of AKI in humans; a worldwide meta-analysis
of hospital-acquired AKI using the KDIGO definition found a pooled
incidence of 21.6% (95% CI, 19.3-24.1).14 Other studies focusing on
predominantly intensive care unit populations report higher preva-
lence, up to 67%.1 In humans, kidney injury can be accompanied by
other organ system failure, especially in critically ill patients, and
development of AKI is related to disease severity.1,2,14 Overall,
despite the majority of horses in this study being admitted as an
emergency (92.3%) and predominantly for gastrointestinal disorders,
they appeared less systemically compromised than the human hospital
populations that have been studied previously. Indeed, our study also
included a number of horses hospitalized for treatment of orthopedic
disorders in which generalized systemic disease would not be
expected. In both univariable and multinomial regression analysis, the
association between SIRS and the development of AKI did not reach
significance. This is contrary to existing evidence from other species
of association between level of systemic illness and development of
AKI. Due to the retrospective nature of this study, missing data meant
SIRS status was not established in 121 horses; this could have pre-
disposed to type 2 errors. Larger numbers in this subset analysis might
have added significance to this observation.
4.2 | Risk factors
Baseline blood samples were taken within 24 hours of admission.
Although the majority of these were likely to have been taken during
admission, this could not be confirmed retrospectively. In addition,
treatments administered by owners and referring veterinarians before
referral were not assessed. Therefore, some potentially nephrotoxic
treatments will have been administered before the baseline sCr being
established, confounding risk factor analysis.
There was no association between age, breed, or sex on the pres-
ence of azotemia or development of AKI. In humans, advanced age
and female sex are associated with increased susceptibility to AKI,
and age over 65 years is associated with reduced recovery rates fol-
lowing kidney injury.9 This is due to age-associated structural and
TABLE 2 Multinomial logistic
regression model identifying associations
between risk factors and either the
development of acute kidney injury
(stages 1-3) or the presence of azotemia
on baseline with reference to horses with
no kidney dysfunction (stage 0)
Stage 0 vs stages 1-3 Stage 0 vs azotemia
OR 95% CI P-value OR 95% CI P-value
(Intercept) 0.073 0.02-0.2 <.001 0 NA <.001
SIRS 0.15 0.02-1.07 .06 NS NS NS
Tetracycline 0.015 0-1.62 .08 NS NS NS
Hypovolemia NS NS NS 8.6 1.8-41.1 .17
Number of diagnoses NS NS NS 4.1 1.5-11.2 .16
Abbreviations: CI, confidence interval; NS, Not significant in univariable therefore not included in
multinomial model; OR, odds ratio; SIRS, systemic inflammatory response syndrome.
F IGURE 1 Comparison of survival to
discharge curves for horses with no
kidney disease (S0) (black solid line), those
that developed an acute kidney injury
while hospitalized (S1-S3) (red dashed
line), and those that had azotemia on
arrival (green dotted line) by the Kaplan-
Meier method (log-rank test, P < .05)
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functional renal deterioration, decreased renal reserve, and a high
level of comorbidities in the geriatric population.9,18 The median age
of horses in this population was 9 years, with only 64 of 325 (19.7%)
horses ≥15 years of age, whereas the average age of adult humans
with hospital-acquired AKI is 61 years.14 Our equine study population
is relatively younger group of mammals presenting with acute disor-
ders than studied hospitalized aged human populations, who are likely
to have chronic disease and multiple comorbidities.
Multinomial logistic regression did not identify any clinical or labo-
ratory diagnoses significantly associated with azotemia or develop-
ment of AKI (Table 2). This is unexpected as although little studied in
horses, renal hypoperfusion secondary to hypovolemia and kidney
injury secondary to systemic inflammation are considered common
mechanisms for development of kidney injury in other species.19
Indeed, renal disease secondary to gastrointestinal disease in horses
has been appreciated for some time, and an association has been
shown between kidney injury and gastrointestinal lesions that involve
sequestration and loss of fluid and electrolytes, such as diarrhea or
gastric reflux.8,20 In the current study, risk factor analysis of the subset
of 80 horses positively identified with SIRS was not possible due to
small group sizes.
No association was identified in this study between treatments
and the development of AKI, although care must be taken in interpre-
tation as subdivision of horses has reduced the power of this analysis.
In a previous study of horses with colic and colitis, no association was
identified between differences in treatments, including NSAIDs,
aminoglycoside antibiotics or administration of IV fluids, and resolu-
tion of azotemia, suggesting that treatments did not influence resolu-
tion of kidney injury.8 This could reflect clinician choice; horses with
azotemia or considered at risk of AKI might have been less likely to
receive nephrotoxic drugs. A larger study would be useful to be quan-
tify the use of drugs with nephrotoxic effects and possible association
with AKI.
4.3 | Survival
In this study, no significant difference was identified between horses
with azotemia or AKI and survival to discharge, unlike the direct corre-
lation between the severity of AKI and the risk of non-survival in
humans.2,3,21,22
Previous studies have documented an association between the
presence of azotemia on admission and decreased survival to dis-
charge.7,8,23,24 These studies included different populations to that
described in the current study; septic pleuropneumonia, colitis, and
equine neorickettsiosis are diseases that carry a significant risk of
hypovolemia as part of their pathophysiology, and, therefore, renal
hypoperfusion is likely to be a more prominent feature in these
populations than in the current study where only 43 horses were
identified as hypovolemic on admission. In addition, an association
between increased severity (>10 mg/dL) and persistence of azotemia
over 72 hours has been associated with decreased survival.7,8 The
highest admission sCr in this study population was 3.5 mg/dL and sCr
normalized during hospitalization for all horses in the azotemia group;
therefore, the severity of azotemia was less than previously studied
populations. A numerical 17% difference in survival to discharge
between azotemia (71.4%, 95% CI, 45.4-88.3) and S0 (88.6%, 95% CI,
84.2-91.9) horses was observed (P = .08; Figure 1); increased sample
size would be required to investigate this further. Based on the data
collected, a sample size estimate that would identify a 10% difference
in survival between the groups, as indicated in this study, with 80%
power and 95% confidence would require 699 horses.
The majority of horses in this study that developed AKI were clas-
sified as S1 (13.5%), with only 2 S2 animals (1.2%) and no S3 horses.
The severity of AKI in this population is therefore less than that in a
generalized hospitalized human population where approximately
11.5% are S1, 4.8% S2, and 4.0% S3 using the KDIGO criteria. The
death rates for these groups were 15.9%, 28.5%, and 47.8%, respec-
tively, identifying a statistically significant increase in non-survival
with increasing AKI stage in humans.14 These results are mirrored in
dogs.22 This might be attributable to the difference in the level of
intensive care that can be provided to the different species.25
4.4 | Limitations
The investigation of AKI is currently limited by the lack of a sensitive
diagnostic test; sCr is a commonly used clinical indicator of glomerular
filtration rate (GFR). However, it is an insensitive marker of renal func-
tion, as it increases only after an approximately 75% loss of GFR. In
addition, sCr can vary with age, breed, sex, and muscle mass.26
Although currently gold standard, the Jaffe reaction for measurement
of sCr is prone to interference both by a number of organic com-
pounds (pseudochromogens), including bilirubin and glucose, and vari-
ous antibiotics.27,28 Other, more sensitive biomarkers of renal
function could become available. Symmetric dimethylarginine (SDMA)
is formed from the methylation of L-arginine in cells and is excreted
solely by the kidneys and more accurately reflects GFR than sCr in
humans, dogs, and cats; concentrations increase in response to a 40%
loss of GFR, and it is less affected by extrinsic factors such as low
muscle mass, sex, and age.26,29-31 Reference ranges for SDMA in adult
horses have been established (Data on file at IDEXX Laboratories, Inc,
Westbrook, Maine), and preliminary studies have identified that vari-
ability between healthy draft horses was low, with no effect of age or
sex.32 In addition, biomarkers of renal injury have diagnostic potential.
Increased urinary matrix metalloproteinase-9 has been identified in
horses with colic and might be related to early renal tubular damage.33
Other direct biomarkers of renal injury, including neutrophil
gelatinase-associated lipocalin, clusterin, cystatin B, and inosine have
yet to be investigated.
This study was limited to identifying the association between
changes in sCr on short-term survival (to discharge). In humans, it is
reported that a 25% increase in sCr in the first week postoperatively
is associated with decreased long-term (>8 years) survival.34 There-
fore, long-term follow-up would be valuable in future research to
investigate delayed or long-term effects of kidney injury. Additionally,
only horses older than 3 months were included in this study in order
to eliminate the confounding effects of spurious hypercreatininemia
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and immature renal metabolism.35 Because of these factors, identify-
ing renal disease in foals is a unique diagnostic challenge and specific
biomarkers of renal function in this population would be valuable.
5 | CONCLUSIONS
The prevalence of hospital-acquired AKI was 14.8% in this population
of horses, and AKI severity was lower than has been observed in
other species. In human and canine patients, systemic illness predis-
poses to AKI, and severity of AKI is associated with non-survival.
However, the presence of azotemia within 24 hours of admission or
the development of an AKI while hospitalized did not affect survival
to discharge in this population of horses. Further investigation is
required to identify more sensitive markers of equine AKI and the
impact of AKI in critically ill equine patients.
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